Diagnostic, Prospective, Comparative, Multicentric Study of the PET / CT With 68Ga-DOTANOC Versus Conventional Imaging Procedures (octréoscan ® Scintigraphy and CT / MRI) in the Assessment of in Gastroenteropancreatic Neuroendocrine Tumors
Inclusion Criteria:
- Age over 18 years
- effective contraception or exclusion of pregnancy dosage of beta-HCG in women of
childbearing age
- Fortuitous discovery of suggestive tumors of TE-GEP with well documented conventional
imaging (multiphase CT; MRI, US endoscopy) associated or not associated with
clinical or biological signs of TE-GEP tumors (increase in tumor markers) OR
- histologically proven GEP-TE (WHO classification 2010 (26) well differentiated in the
initial staging OR
- Suspicion of recurrence or progression of well differentiated TE-GEP tumors on
conventional imaging or laboratory tests (increase in tumor markers)
- Informed consent and patient's written
- Affiliation to an insurance
Exclusion Criteria:
- Multiple endocrine neoplasia
- TE GEP tumor not differentiated
- Pregnancy and lactation
- Persons protected by law
- Restlessness, inability to lie still hold at least 1 hour; Claustrophobia
- Poor compliance predictable or inability to undergo medical test for geographical,
social or psychological
- Treatment with radiotherapy, chemotherapy or other antitumor treatment within 6 weeks
of previous morphological and scintigraphic examinations. In case of treatment with
somatostatin analogues delayed, scans will be performed 4 weeks after the last
injection. However, a shorter period may be observed to avoid to do again the initial
assessment exams.
- malignancy except basal cell cancers and cancer in situ of the cervix
- Contraindication of injection of a contrast agent necessary for the production of
multiphase scanner.
- Patients who had a CT scan without injection of contrast material can not participate
in the study